PRINCETON, N.J., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full-year 2019 financial results on Wednesday, February 19, 2020 prior to market open.

PRINCETON, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced the pricing of $500,000,000 aggregate principal amount of 0.5% convertible senior notes due 2025 (the “Notes”). The Notes were offered and sold in a private placement solely to

PRINCETON, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has amended and extended its credit facility and commenced a private offering of convertible senior notes. Amendment and Extension of Credit Facility Integra today

Fourth quarter 2019 reported revenue is expected to be at or near the low end of the previously communicated guidance range of $395 to $400 million, representing organic revenue growth of slightly less than 5% and reported growth of approximately 3%; For the full-year 2020, the company is providing

PLAINSBORO, N.J., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced President and Chief Executive Officer Peter Arduini will speak at the 38 th Annual J.P.

PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Carrie Anderson, chief financial officer, will present at the Piper Jaffray 31 st Annual Healthcare Conference in New York

PLAINSBORO, NJ, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the 28 th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona on Tuesday, November 12, 2019 at 1:15 p.m.

Reported revenues increased 3.6% to $379.1 million; organic revenues increased 4.7%  GAAP and adjusted earnings per diluted share were $(0.32) and $0.68, respectively The Company is tightening the range for its full-year reported revenue guidance and reaffirming full-year organic revenue growth

PLAINSBORO, N.J., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2019 financial results on Thursday, October 24, 2019, prior to market open.

PLAINSBORO, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- During the 18 th European Burns Association (EBA) Congress, which took place in Helsinki, Finland, from 4 to 7 September 2019, Integra LifeSciences announced its support for EBA through an educational grant for their “Share your Care” junior

PLAINSBORO, N.J., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART ), a leading global medical technology company, today announced positive findings from its Cadence® Total Ankle System  retrospective study. Tim Daniels, MD, FRCSC, Professor, University of

Acquisition Adds New, Minimally Invasive Platform for Neurosurgery PLAINSBORO, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, announced today that it has acquired Rebound Therapeutics, developers of

PLAINSBORO, N.J., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following healthcare conferences in September: On Thursday, September 5, 2019 at 1:55 p.m.

Adds Unique Solution to Integra’s Neurocritical Care Offering PLAINSBORO, N.J., July 29, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that it has acquired Arkis Biosciences Inc.

Reported revenues increased 4.8% to $383.6 million; organic revenues increased 6.6%  GAAP and adjusted earnings per diluted share were $0.34 and $0.73, respectively The Company reaffirms revenue guidance and updates EPS guidance PLAINSBORO, N.J., July 24, 2019 (GLOBE NEWSWIRE) -- Integra